A phase ii study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)

被引：0
|
作者：
Younes, A [1 ]
Rodriguez, M [1 ]
Pro, B [1 ]
McLaughlin, P [1 ]
Romaguera, J [1 ]
Hagemeister, F [1 ]
Wang, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
201
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [1] A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Oki, Y
    Pro, B
    Delpassand, E
    Ballaster, V
    McLaughlin, P
    Romaguera, J
    Wang, M
    Hagemeister, FB
    Younes, A
    BLOOD, 2004, 104 (11) : 720A - 720A
  • [2] Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL).
    Younes, A
    Pro, B
    Rodriguez, MA
    Romaguera, JE
    McLaughlin, P
    Wang, M
    Hagemeister, FB
    Dang, NH
    Neelapu, S
    Podoloff, D
    BLOOD, 2005, 106 (11) : 689A - 690A
  • [3] Phase II study of Yttrium 90 (90Y) lbritumomab tiuxetan (Zevalin®) in patients with relapsed and refractory mantle cell lymphoma (MCL).
    Wang, Michael
    Oki, Yasuhiro
    Pro, Barbara
    Romaguera, Jorge Enrique
    Rodriguez, Maria Alma
    Samaniego, Felipe
    McLaughlin, Peter
    Hagemeister, Frederick
    Neelapu, Sattva
    Podoloff, Donald
    Samuels, Barry
    Loyer, Evelyne
    Zhou, Yuhong
    Younes, Anas
    BLOOD, 2006, 108 (11) : 767A - 767A
  • [4] A phase II study of 90Yttrium-ibritumomab (Zevalin) for the treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Younes, A
    Pro, B
    Delpassand, E
    McLaughlin, P
    Romaguera, J
    Wang, M
    BLOOD, 2003, 102 (11) : 406A - 406A
  • [5] Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Wang, Michael
    Oki, Yasuhiro
    Pro, Barbara
    Romaguera, Jorge Enrique
    Rodriguez, Maria Alma
    Samaniego, Felipe
    McLaughlin, Peter
    Hagemeister, Frederick
    Neelapu, Sattva
    Copeland, Amanda
    Samuels, Barry I.
    Loyer, Evelyne M.
    Ji, Yuan
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5213 - 5218
  • [6] RADIOIMMUNOTHERAPY OF (90Y)-IBRITUMOMAB TIUXETAN FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA
    Yoshida, Isao
    Kogure, Yuuki
    Kajihara, Makoto
    ANNALS OF ONCOLOGY, 2014, 25
  • [7] Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term responses in patients with relapsed or refractory follicular lymphoma (FL).
    Schilder, RJ
    Witzig, TE
    Flinn, I
    Gordon, LI
    Emmanouilides, C
    Wang, H
    Vo, K
    Molina, A
    BLOOD, 2004, 104 (11) : 719A - 719A
  • [8] Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin)
    Gregory, SA
    SEMINARS IN ONCOLOGY, 2003, 30 (06) : 17 - 22
  • [9] 90Y-ibritumomab tiuxetan (90Y-Zevalin) radioimmunotherapy as a consolidation strategy in mantle cell lymphoma (MCL) patients
    Jurczak, W.
    Giza, A.
    Hubalewska-Dydejczyk, A.
    Sowa-Staszczak, A.
    Glowa, B.
    Szostek, M.
    Krochmalczyk, D.
    Wegrzyn, J.
    Knopinska-Posluszny, W.
    Zdziarska, B.
    Kyrcz-Krzemien, S.
    Poplawska, L.
    Walewski, J.
    Wrobel, T.
    Skotnicki, A. B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S168 - S168
  • [10] Phase II study of 90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma
    Lossos, Izidore S.
    Fabregas, Jesus C.
    Koru-Sengul, Tulay
    Miao, Feng
    Goodman, Deborah
    Serafini, Aldo N.
    Hosein, Peter J.
    Stefanovic, Alexandra
    Rosenblatt, Joseph D.
    Hoffman, James E.
    LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1750 - 1755
12345